3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
2
NET
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Breast
1
Conditions
Prostatic Neoplasms
1
Neuroendocrine Tumors
1
Colorectal Neoplasms
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
lutetium Lu 177 dotatate
29
Magnetic Resonance Spectroscopy
15
Everolimus
10
pembrolizumab
9
Specimen Handling
9
cabozantinib
7
Nivolumab
7
Lutetium-177
6
surufatinib
5
lenvatinib
5
Octreotide
5
Capecitabine
5
177Lu-octreotide, DOTA(0)-Tyr(3)-
5
olaparib
4
lanreotide
4
gallium Ga 68 dotatate
4
amino-acid, glucose, and electrolyte solution
4
X-Rays
4
Lutetium
4
Ipilimumab
4
Injections
4
Fluorodeoxyglucose F18
4
copper dotatate CU-64
3
atezolizumab
3
Temozolomide
3
Cyclophosphamide
3
Carboplatin
3
pasireotide
2
fludarabine phosphate
2
fludarabine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
gadoterate meglumine
×
NET
×
1 year
×
Clear all
NCT04373564
2026-01-22
ODYSSEY
Guerbet
Phase 4
Recruiting
2,076 enrolled